$3.40
0.3511.48%
At close: -
$2.90
-0.50-14.71%
After Hours: Dec 27, 9:27 AM EDT
Comments
Loading...
Latest news for CytoMed Therapeutics (NASDAQ:GDTC) Stock
CytoMed Therapeutics Stock (NASDAQ: GDTC)
Categories: All
Wednesday, November 20, 2024
Thursday, October 10, 2024
Thursday, October 03, 2024
Wednesday, July 17, 2024
Tuesday, June 11, 2024
Wednesday, March 20, 2024
Monday, March 18, 2024
Monday, March 04, 2024
Wednesday, February 14, 2024
Friday, February 09, 2024
Wednesday, February 07, 2024
Monday, January 29, 2024
Monday, January 15, 2024
Wednesday, December 27, 2023
Tuesday, December 05, 2023
Monday, December 04, 2023
Friday, November 17, 2023
Monday, October 09, 2023
Monday, September 25, 2023
Tuesday, August 29, 2023
Friday, July 21, 2023
Thursday, July 13, 2023
Wednesday, July 12, 2023
- CytoMed Therapeutics Limited shares are tradi...
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket
Tuesday, July 11, 2023
- Shares of low-float CytoMed Therapeutics are ...
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- Dow Jumps Over 100 Points; US Small Business Optimism Index Tops Estimates
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Friday, July 07, 2023
Thursday, July 06, 2023
Friday, May 12, 2023
Wednesday, May 10, 2023
Tuesday, May 09, 2023
- CytoMed Therapeutics Shares Resume Trading Fo...
- CytoMed Therapeutics Shares Halted On Circuit...
- CytoMed Therapeutics Shares Resume Trade Foll...
- CytoMed Therapeutics Shares Halted On Circuit...
- CytoMed Therapeutics Limited Announces Collaboration With MD Anderson Cancer Center To Advance Allogeneic Off-The-Shelf Gamma Delta T Cells In Oncology